Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Melilotus Officinalis
Brand Name
Melilotus Officinalis
Generic Name
Melilotus Officinalis
Active Ingredient
Melilotus Officinalis TopCategory
Nitrate Vasodilator [EPC]
Variants
8
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 200 [hp_C]/1 | PELLET | ORAL | 37662-1143 |
| 12 [hp_C]/1 | PELLET | ORAL | 37662-1140 |
| 30 [hp_C]/1 | PELLET | ORAL | 37662-1141 |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Melilotus Officinalis, you must consult a qualified healthcare professional.
| 1 [hp_M]/1 | PELLET | ORAL | 37662-1145 |
| 100 [hp_C]/1 | PELLET | ORAL | 37662-1142 |
| 500 [hp_C]/1 | PELLET | ORAL | 37662-1144 |
| 6 [hp_C]/1 | PELLET | ORAL | 37662-1139 |
| 1 [hp_Q]/1 | PELLET | ORAL | 37662-1146 |
Detailed information about Melilotus Officinalis
Melilotus Officinalis Top is a pharmacological agent classified primarily as a Nitrate Vasodilator and an allergenic extract. It is utilized in clinical settings for vascular support and immunotherapy, requiring precise medical oversight.
Dosage for Melilotus Officinalis Top varies significantly based on the condition being treated and the specific formulation used. For chronic venous insufficiency (CVI) and lymphatic support, healthcare providers typically prescribe standardized oral extracts. A common adult dosage range is 200 mg to 400 mg of standardized extract, taken two to three times daily. This often equates to a total daily coumarin intake of approximately 15 mg to 30 mg.
In the context of allergenic extracts used for immunotherapy, the dosage is highly individualized. It begins with extremely low concentrations (often 1:100,000 w/v) and is gradually increased by an allergist based on the patient's skin test reactivity and clinical tolerance. This is known as the "build-up phase," followed by a "maintenance phase" where the dose remains constant for several years.
The safety and efficacy of Melilotus Officinalis Top in children have not been established. In most clinical guidelines, its use is not recommended for pediatric patients under the age of 18. If an allergist determines that a child requires allergenic immunotherapy involving Melilotus, the dosing will be strictly controlled in a clinical setting with emergency equipment available.
Because the metabolites of Melilotus Officinalis Top are primarily excreted by the kidneys, patients with impaired renal function (reduced kidney function) may require lower doses. Monitoring of kidney function (serum creatinine and GFR) is recommended for those with Stage 3 or higher chronic kidney disease.
The liver is responsible for the metabolism of the active compounds in Melilotus. Patients with active liver disease, such as hepatitis or cirrhosis, should avoid this medication. In cases of mild hepatic impairment, extreme caution and frequent liver function tests (LFTs) are mandatory, as coumarin-containing products have a historical association with hepatotoxicity in sensitive individuals.
Geriatric patients often have a higher prevalence of venous issues but may also have reduced organ clearance. It is generally advised to start at the lower end of the dosing spectrum (e.g., 100-200 mg daily) and titrate upward based on tolerance and clinical response.
If you miss a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and return to your regular routine. Do not double the dose to make up for a missed one, as this increases the risk of side effects.
Signs of an overdose of Melilotus Officinalis Top may include severe nausea, vomiting, dizziness, headache, and in extreme cases, signs of liver distress (yellowing of the eyes or skin). If an overdose is suspected, contact your local poison control center or seek emergency medical attention immediately. In the case of allergenic extract overdose (during immunotherapy), the primary concern is anaphylaxis, characterized by difficulty breathing, swelling of the throat, and a rapid drop in blood pressure.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, especially if you are undergoing immunotherapy.
Most patients tolerate Melilotus Officinalis Top well, but some may experience mild adverse reactions. The most common side effects include:
Melilotus Officinalis Top is a potent pharmacological agent. It should only be used under the direction of a qualified healthcare provider. Patients must be aware that botanical origin does not equate to an absence of risk. Because it acts as a Nitrate Vasodilator, it can affect blood pressure and interact with other cardiovascular medications. Furthermore, its role as an allergenic extract means it carries a risk of stimulating the immune system in unpredictable ways.
No FDA black box warnings for Melilotus Officinalis Top. However, users of the allergenic extract form should heed the general class warnings for all immunotherapy products, which highlight the risk of life-threatening allergic reactions.
Certain medications should never be combined with Melilotus Officinalis Top due to the risk of severe adverse events:
Melilotus Officinalis Top must NEVER be used in the following circumstances:
Melilotus Officinalis Top is generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown that coumarin can cross the placental barrier. While the coumarin in Melilotus is not the same as the teratogenic warfarin, the potential for fetal harm cannot be entirely ruled out. Use during pregnancy is not recommended, especially during the first trimester when organogenesis (organ formation) occurs.
It is unknown whether the active constituents of Melilotus Officinalis Top pass into human breast milk. Because many small molecules do enter breast milk, and the infant's liver is not fully developed to process coumarin, breastfeeding mothers should avoid this medication. If treatment is essential, a healthcare provider may recommend switching to infant formula.
Melilotus Officinalis Top is not FDA-approved for use in children. The vascular system and immune responses of children differ significantly from adults, and the risks of hepatotoxicity or severe allergic reactions are not well-characterized in this population. Its use should be restricted to clinical trials or under the extreme supervision of a pediatric specialist.
Melilotus Officinalis Top functions as a Nitrate Vasodilator by promoting the release of endogenous nitric oxide from the vascular endothelium. This activates the cGMP pathway, leading to the dephosphorylation of myosin light chains and the subsequent relaxation of vascular smooth muscle. Simultaneously, its coumarin components act as lymphokinetic agents. They increase the number and activity of macrophages, which migrate to areas of protein-rich edema and break down the accumulated proteins into smaller fragments. This increases the osmotic pressure within the lymphatic vessels, facilitating the drainage of interstitial fluid and reducing swelling.
The dose-response relationship of Melilotus is characterized by a gradual onset. While vasodilation may occur within hours, the full anti-edematous (swelling-reducing) effects often take 2 to 4 weeks of consistent use to become clinically evident. Tolerance to the nitrate-like effects is less common than with synthetic nitrates, but patients should still follow a dosing schedule that allows for a "nitrate-low" period if recommended by their doctor.
Common questions about Melilotus Officinalis
Melilotus Officinalis Top is primarily used to treat symptoms of chronic venous insufficiency, such as leg swelling, pain, and heaviness. Because it is classified as a nitrate vasodilator, it helps relax blood vessels and improve overall circulation. Additionally, it is used in the management of lymphedema by stimulating the lymphatic system to remove excess fluid from tissues. In specialized clinical settings, it also serves as an allergenic extract for diagnosing and treating specific plant-related allergies through immunotherapy. It is not a first-line treatment for acute heart conditions but rather a supportive therapy for vascular and lymphatic health.
The most frequently reported side effects are generally mild and include gastrointestinal issues like nausea, indigestion, or stomach discomfort. Some patients may also experience headaches or a feeling of lightheadedness, which is common with medications that cause blood vessels to widen. Flushing of the skin and mild diarrhea have also been noted in clinical observations. Most of these symptoms are transient and tend to disappear as the body acclimates to the medication. However, if these effects persist or worsen, you should consult your healthcare provider to discuss a possible dose adjustment.
Drinking alcohol while taking Melilotus Officinalis Top is generally discouraged by medical professionals. Alcohol itself acts as a vasodilator, and when combined with a nitrate vasodilator like Melilotus, it can lead to an additive effect that causes blood pressure to drop significantly. This can result in severe dizziness, fainting, or an increased risk of falls, particularly in the elderly. Furthermore, both substances are processed by the liver, and their combination can place unnecessary stress on hepatic function. It is best to discuss your alcohol consumption habits with your doctor before starting this treatment.
The safety of Melilotus Officinalis Top during pregnancy has not been definitively established through clinical trials, leading to its classification as Category C. While it does not contain the same high risks as synthetic anticoagulants, its active components can cross the placenta and potentially affect fetal development. Most healthcare providers recommend avoiding its use during pregnancy unless the medical necessity is absolute and no safer alternatives exist. Breastfeeding mothers should also avoid the drug, as the impact on a nursing infant is currently unknown. Always seek a specialist's opinion if you are pregnant or planning to become pregnant while on this medication.
While the vasodilatory effects of Melilotus Officinalis Top may begin shortly after ingestion, the visible reduction in swelling and improvement in venous symptoms typically take longer. Most patients begin to notice a significant difference in leg heaviness and edema after approximately 2 to 4 weeks of consistent daily use. This delay is because the medication needs time to stimulate macrophage activity and clear protein-rich fluid from the lymphatic system. It is important to continue taking the medication as prescribed even if you do not see immediate results. If there is no improvement after 6 weeks, your doctor may re-evaluate your treatment plan.
For patients taking Melilotus Officinalis Top for venous or lymphatic issues, the medication can generally be stopped without experiencing a withdrawal syndrome. However, doing so may cause a return of symptoms like swelling and leg pain fairly quickly. If you are using the medication as part of an allergenic immunotherapy program, stopping suddenly is highly discouraged, as it can disrupt the desensitization process and increase the risk of future allergic reactions. You should always consult with your prescribing physician before discontinuing any long-term pharmacological treatment to ensure it is done safely and at the appropriate time.
If you miss a dose of Melilotus Officinalis Top, you should take it as soon as you realize it has been missed. If it is almost time for your next scheduled dose, it is safer to skip the missed dose and simply continue with your regular schedule. You should never take two doses at once to compensate for a missed one, as this can increase the concentration of the drug in your system and heighten the risk of side effects like dizziness or nausea. Maintaining a consistent dosing schedule is the best way to ensure the medication remains effective. Setting a daily alarm can help you stay on track.
There is no clinical evidence to suggest that Melilotus Officinalis Top causes weight gain as a direct side effect. In fact, for patients suffering from significant lymphedema or venous edema, the medication may actually lead to a slight decrease in weight as excess fluid is drained from the tissues and excreted by the body. If you notice a sudden or unexplained increase in weight while taking this medication, it is more likely related to other health factors or a change in your underlying condition. You should report any rapid weight changes to your doctor, as they may indicate a need to adjust your overall cardiovascular management.
Melilotus Officinalis Top has several potential interactions, particularly with blood thinners and other heart medications. Because it has vasodilatory and mild antiplatelet properties, taking it with drugs like aspirin, warfarin, or clopidogrel can increase the risk of bruising and bleeding. It can also interact with other blood pressure-lowering drugs, potentially causing your blood pressure to fall too low. It is essential to provide your healthcare provider with a comprehensive list of all prescription drugs, over-the-counter medications, and herbal supplements you are currently taking. This allows them to screen for dangerous interactions and ensure your treatment is safe.
Melilotus Officinalis Top is essentially a botanical extract, and while it is not 'generic' in the way a synthetic drug like lisinopril is, it is available from various manufacturers under different brand names and as a standardized herbal extract. In the United States, it is often found in compounded preparations or as a component of allergenic extracts used by specialists. The availability and regulation can vary significantly by country. When purchasing this medication, it is crucial to ensure you are getting a standardized product from a reputable source, as the concentration of active coumarins can vary widely between non-standardized preparations.
> Warning: Stop taking Melilotus Officinalis Top and call your doctor immediately if you experience any of the following:
Prolonged use of Melilotus Officinalis Top requires periodic monitoring. The primary long-term concern is the potential for cumulative stress on the liver. Clinical studies on standardized coumarin extracts suggest that long-term use (over 6 months) is generally safe for most, but liver function tests should be performed at regular intervals (e.g., every 3 to 6 months) to ensure continued safety. There is no evidence of dependency or withdrawal syndromes associated with long-term use.
No FDA black box warnings currently exist for Melilotus Officinalis Top. However, it is important to note that the FDA requires stringent labeling for all allergenic extracts regarding the risk of severe systemic reactions, including anaphylaxis. These products must only be administered by healthcare professionals prepared to manage such emergencies.
Report any unusual symptoms or persistent side effects to your healthcare provider. Monitoring your body's response is a key part of successful therapy.
If you are prescribed Melilotus Officinalis Top for long-term use, your doctor will likely require the following:
Because this medication can cause dizziness or mild lightheadedness, especially during the initiation phase, patients should observe how they react before driving or operating heavy machinery. If you feel dizzy or faint, avoid these activities until the feeling passes.
Alcohol should be consumed with extreme caution, if at all, while taking Melilotus Officinalis Top. Alcohol can exacerbate the vasodilatory effects, leading to a significant drop in blood pressure and increased dizziness. Additionally, both alcohol and Melilotus are processed by the liver, and combining them increases the risk of hepatic strain.
For vascular indications, Melilotus can usually be stopped without a complex tapering schedule. However, for allergenic immunotherapy, stopping the injections abruptly can result in a loss of the desensitization progress. Always consult your doctor before stopping any long-term medication.
> Important: Discuss all your medical conditions, especially liver or heart issues, with your healthcare provider before starting Melilotus Officinalis Top.
Melilotus Officinalis Top may interfere with certain laboratory results:
For each interaction, the mechanism usually involves either a pharmacodynamic effect (additive effects on blood vessels or clotting) or a pharmacokinetic effect (competition for liver enzymes).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is vital for your safety.
Conditions requiring a careful risk-benefit analysis by a physician include:
Patients who are allergic to other members of the Fabaceae family (such as alfalfa, soy, peanuts, or chickpeas) may have an increased risk of a cross-allergic reaction to Melilotus Officinalis Top. Additionally, those sensitive to other coumarin-containing plants (like woodruff or tonka beans) should be cautious.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Melilotus Officinalis Top. Be honest about all past health issues.
Patients over the age of 65 may be more sensitive to the effects of Melilotus Officinalis Top. There is an increased risk of dizziness and falls due to the drug's vasodilatory effects. Furthermore, elderly patients are more likely to be on multiple medications (polypharmacy), increasing the risk of drug interactions. Renal and hepatic clearance often decline with age, so lower starting doses are strongly advised.
For patients with a Glomerular Filtration Rate (GFR) below 60 mL/min, the clearance of Melilotus metabolites may be reduced. While no specific formula for dose reduction exists, clinicians often reduce the frequency of dosing (e.g., once daily instead of twice) and monitor for signs of accumulation.
Melilotus is contraindicated in patients with Child-Pugh Class B or C hepatic impairment. In Class A (mild impairment), the drug should be used with extreme caution, with LFTs performed every 2 weeks for the first two months of therapy.
> Important: Special populations require individualized medical assessment. Never share your medication with others, especially those in these sensitive groups.
| Parameter | Value |
|---|---|
| Bioavailability | ~80% (Oral) |
| Protein Binding | 30% - 40% (Primarily Albumin) |
| Half-life | 1 - 4 hours |
| Tmax | 1 - 1.5 hours |
| Metabolism | Hepatic (CYP2A6) |
| Excretion | Renal (>90%) |
Melilotus Officinalis Top is classified as a Nitrate Vasodilator [EPC]. It is grouped with other agents that influence vascular tone. In the context of its allergenic uses, it is categorized as a Non-Standardized Plant Allergenic Extract. It shares therapeutic space with other venoactive drugs like Diosmin and Hesperidin, though its specific nitrate-based mechanism is distinct.